

**IMMUNE
COMPLEX
CORPORATION**

March 23, 2000

George B. Thornton, Ph.D.
Chief Executive Officer
Immune Complex Corporation
3347 Industrial Court
San Diego, California 92121

Dear Ben,

Please provide me with copies of the two patent applications regarding (1) the stabilization of HBcAg-hybrid particles, and (2) the production of the malaria vaccine (i.e. PF 3.1). As you are aware, I have asked you and Ashley previously about the status of these applications and when I would be able to provide my input.

I designed all the antigenicity, serology and immunology experiments, provided and analyzed all the antigenicity, serology and immunology data, which were integral and necessary to the discoveries. The immunologic analysis allowed Ashley and I to constantly design, test and improve one construct after another, which ultimately led to the production of stable HBcAg-hybrid particles and to the design of the final vaccine candidate (i.e. PF 3.1). I should at least proof read these two applications before they are submitted to the patent office. I assume this is routine for an inventor on a patent. I am sure the fact that I have not been shown these applications to date is a mere oversight. My concern is the past history regarding the matter of the two P. falciparum SBIR grant applications. You have acknowledged on multiple occasions that I should have been listed as a co-investigator on these applications and I had requested that I be listed as a co-investigator on these applications, yet the company failed to do so.

Because I will need time to review the applications and I realize the applications are about to be submitted, I would appreciate receiving this material as soon as possible (i.e. within the next few days).

Sincerely,



David R. Milich, Ph.D.
CSO, ICC

Cc: Ed Gamson, Patent Attorney
Ashley Birkett, Ph.D., Director of Research, ICC

BEST AVAILABLE COPY